Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164 von Le, Dung T, Kim, Tae Won, Van Cutsem, Eric, Geva, Ravit, Jäger, Dirk, Hara, Hiroki, Burge, Matthew, O'Neil, Bert, Kavan, Petr, Yoshino, Takayuki, Guimbaud, Rosine, Taniguchi, Hiroya, Elez, Elena, Al-Batran, Salah-Eddin, Boland, Patrick M, Crocenzi, Todd, Atreya, Chloe E, Cui, Yi, Dai, Tong, Marinello, Patricia, Diaz, Jr, Luis A, André, Thierry

Volltext

Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study von Shen, Lin, Kato, Ken, Kim, Sung-Bae, Ajani, Jaffer A, Zhao, Kuaile, He, Zhiyong, Yu, Xinmin, Shu, Yongqian, Luo, Qi, Wang, Jufeng, Chen, Zhendong, Niu, Zuoxing, Zhang, Longzhen, Yi, Tienan, Sun, Jong-Mu, Chen, Jianhua, Yu, Guohua, Lin, Chen-Yuan, Hara, Hiroki, Bi, Qing, Satoh, Taroh, Pazo-Cid, Roberto, Arkenau, Hendrick-Tobias, Borg, Christophe, Lordick, Florian, Li, Liyun, Ding, Ningning, Tao, Aiyang, Shi, Jingwen, Van Cutsem, Eric

Volltext

Survival outcomes of esophageal cancer patients with recurrence after curative treatments von Sugawara, Kotaro, Oka, Daiji, Hara, Hiroki, Yoshii, Takako, Ushijima, Hiroki, Kudo, Shigehiro, Fukuda, Takashi

Volltext

Practical guidance for the evaluation of disease progression and the decision to change treatment in patients with advanced gastric cancer receiving chemotherapy von Iwasa, Satoru, Kudo, Toshihiro, Takahari, Daisuke, Hara, Hiroki, Kato, Ken, Satoh, Taroh

Volltext

Influences of intratumoral heterogeneity on assessment of tumor microenvironment in esophageal squamous cell carcinoma von Sugawara, Kotaro, Fukuda, Takashi, Kishimoto, Yutaka, Oka, Daiji, Yoshii, Takako, Hara, Hiroki, Uemura, Yukari, Kawashima, Yoshiyuki, Kanda, Hiroaki, Motoi, Noriko

Volltext

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase... von Bang, Yung-Jue, Kang, Yoon-Koo, Catenacci, Daniel V., Muro, Kei, Fuchs, Charles S., Geva, Ravit, Hara, Hiroki, Golan, Talia, Garrido, Marcelo, Jalal, Shadia I., Borg, Christophe, Doi, Toshihiko, Yoon, Harry H., Savage, Mary J., Wang, Jiangdian, Dalal, Rita P., Shah, Sukrut, Wainberg, Zev A., Chung, Hyun Cheol

Volltext

Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma von Hara, Hiroki, Tahara, Makoto, Daiko, Hiroyuki, Kato, Ken, Igaki, Hiroyasu, Kadowaki, Shigenori, Tanaka, Yoichi, Hamamoto, Yasuo, Matsushita, Hisayuki, Nagase, Michitaka, Hosoya, Yoshinori

Volltext

Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastri... von Nakajima, Takako Eguchi, Yamaguchi, Kensei, Boku, Narikazu, Hyodo, Ichinosuke, Mizusawa, Junki, Hara, Hiroki, Nishina, Tomohiro, Sakamoto, Takeshi, Shitara, Kohei, Shinozaki, Katsunori, Katayama, Hiroshi, Nakamura, Shinichiro, Muro, Kei, Terashima, Masanori

Volltext

Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08 von Masuishi, Toshiki, Tsuji, Akihito, Kotaka, Masahito, Nakamura, Masato, Kochi, Mitsugu, Takagane, Akinori, Shimada, Ken, Denda, Tadamichi, Segawa, Yoshihiko, Tanioka, Hiroaki, Hara, Hiroki, Sagawa, Tamotsu, Watanabe, Takanori, Takahashi, Takao, Negoro, Yuji, Manaka, Dai, Fujita, Hideto, Suto, Takeshi, Takeuchi, Masahiro, Ichikawa, Wataru, Fujii, Masashi

Volltext

Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E) von Yamamoto, Shun, Kato, Ken, Daiko, Hiroyuki, Kojima, Takashi, Hara, Hiroki, Abe, Tetsuya, Tsubosa, Yasuhiro, Nagashima, Kengo, Aoki, Kazunori, Mizoguchi, Yukihiro, Kitano, Shigehisa, Yachida, Shinichi, Shiba, Satoshi, Kitagawa, Yuko

Volltext

SY12-3 Precision medicine for esophageal cancer von Hara, Hiroki

Volltext

Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable... von Terada, Mitsumi, Hara, Hiroki, Daiko, Hiroyuki, Mizusawa, Junki, Kadota, Tomohiro, Hori, Keisuke, Ogawa, Hirofumi, Ogata, Takashi, Sakanaka, Katsuyuki, Sakamoto, Takeshi, Kato, Ken, Kitagawa, Yuko

Volltext

A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer von Yokota, Tomoya, Kato, Ken, Hamamoto, Yasuo, Tsubosa, Yasuhiro, Ogawa, Hirofumi, Ito, Yoshinori, Hara, Hiroki, Ura, Takashi, Kojima, Takashi, Chin, Keisho, Hironaka, Shuichi, Kii, Takayuki, Kojima, Yasushi, Akutsu, Yasunori, Matsushita, Hisayuki, Kawakami, Kentaro, Mori, Keita, Makiuchi, Takashi, Nagumo, Rie, Kitagawa, Yuko

Volltext

TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esoph... von Bando, Hideaki, Kotani, Daisuke, Tsushima, Takahiro, Hara, Hiroki, Kadowaki, Shigenori, Kato, Ken, Chin, Keisho, Yamaguchi, Kensei, Kageyama, Shun-Ichiro, Hojo, Hidehiro, Nakamura, Masaki, Tachibana, Hidenobu, Wakabayashi, Masashi, Fukutani, Miki, Togashi, Yosuke, Fuse, Nozomu, Nishikawa, Hiroyoshi, Kojima, Takashi

Volltext

Low voltage visible light modulation for three colors (red, green, blue) by sputtered lithium niobate thin film von Hara, Hiroki, Yoshinari, Jiro, Sasaki, Kenji, Kikukawa, Takashi, Take, Hiroshi, Mino, Tetsuya, Shimura, Atsushi, Takagi, Yasuhiro, Fukuzawa, Hideaki

Volltext

Visible light modulator by sputter-deposited lithium niobate von Fukuzawa, Hideaki, Yoshinari, Jiro, Hara, Hiroki, Sasaki, Kenji, Take, Hiroshi, Yoshida, Makoto, Shimura, Atsuhi, Kikukawa, Takashi

Volltext

Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head‐and‐neck... von Doki, Yuichiro, Ueno, Makoto, Hsu, Chih‐Hung, Oh, Do‐Youn, Park, Keunchil, Yamamoto, Noboru, Ioka, Tatsuya, Hara, Hiroki, Hayama, Manabu, Nii, Masahiro, Komuro, Keiko, Sugimoto, Mariko, Tahara, Makoto

Volltext

Long‐term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer von Kato, Ken, Doki, Yuichiro, Ura, Takashi, Hamamoto, Yasuo, Kojima, Takashi, Tsushima, Takahiro, Hironaka, Shuichi, Hara, Hiroki, Kudo, Toshihiro, Iwasa, Satoru, Muro, Kei, Yasui, Hirofumi, Minashi, Keiko, Yamaguchi, Kensei, Ohtsu, Atsushi, Kitagawa, Yuko

Volltext

Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the J... von Doi, Toshihiko, Iwasa, Satoru, Muro, Kei, Satoh, Taroh, Hironaka, Shuichi, Esaki, Taito, Nishina, Tomohiro, Hara, Hiroki, Machida, Nozomu, Komatsu, Yoshito, Shimada, Yasuhiro, Otsu, Satoshi, Shimizu, Shin, Watanabe, Morihiro

Volltext

Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (AT... von Takahashi, Masanobu, Kato, Ken, Okada, Morihito, Chin, Keisho, Kadowaki, Shigenori, Hamamoto, Yasuo, Doki, Yuichiro, Kubota, Yutaro, Kawakami, Hisato, Ogata, Takashi, Hara, Hiroki, Muto, Manabu, Nakashima, Yuichiro, Ishihara, Ryu, Tsuda, Masahiro, Motoyama, Satoru, Kodani, Mamoru, Kitagawa, Yuko

Volltext